Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCasals, Gregori
dc.contributor.authorPerramón, Meritxell
dc.contributor.authorCasals, Eudald
dc.contributor.authorPortolés, Irene
dc.contributor.authorFernández-Varo, Guillermo
dc.contributor.authorMorales-Ruiz, Manuel
dc.contributor.authorFranco Puntes, Victor
dc.date.accessioned2021-12-03T10:18:50Z
dc.date.available2021-12-03T10:18:50Z
dc.date.issued2021-04-24
dc.identifier.citationCasals G, Perramón M, Casals E, Portolés I, Fernández-Varo G, Morales-Ruiz M, et al. Cerium oxide nanoparticles: A new therapeutic tool in liver diseases. Antioxidants. 2021 Apr 24;10(5):660.
dc.identifier.issn2076-3921
dc.identifier.urihttp://hdl.handle.net/11351/6649
dc.descriptionHepatocellular carcinoma; Liver regeneration; Nanoceria
dc.description.abstractOxidative stress induced by the overproduction of free radicals or reactive oxygen species (ROS) has been considered as a key pathogenic mechanism contributing to the initiation and progression of injury in liver diseases. Consequently, during the last few years antioxidant substances, such as superoxide dismutase (SOD), resveratrol, colchicine, eugenol, and vitamins E and C have received increasing interest as potential therapeutic agents in chronic liver diseases. These substances have demonstrated their efficacy in equilibrating hepatic ROS metabolism and thereby improving liver functionality. However, many of these agents have not successfully passed the scrutiny of clinical trials for the prevention and treatment of various diseases, mainly due to their unspecificity and consequent uncontrolled side effects, since a minimal level of ROS is needed for normal functioning. Recently, cerium oxide nanoparticles (CeO2NPs) have emerged as a new powerful antioxidant agent with therapeutic properties in experimental liver disease. CeO2NPs have been reported to act as a ROS and reactive nitrogen species (RNS) scavenger and to have multi-enzyme mimetic activity, including SOD activity (deprotionation of superoxide anion into oxygen and hydrogen peroxide), catalase activity (conversion of hydrogen peroxide into oxygen and water), and peroxidase activity (reducing hydrogen peroxide into hydroxyl radicals). Consequently, the beneficial effects of CeO2NPs treatment have been reported in many different medical fields other than hepatology, including neurology, ophthalmology, cardiology, and oncology. Unlike other antioxidants, CeO2NPs are only active at pathogenic levels of ROS, being inert and innocuous in healthy cells. In the current article, we review the potential of CeO2NPs in several experimental models of liver disease and their safety as a therapeutic agent in humans as well.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesAntioxidants;10(5)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectFetge - Malalties - Tractament
dc.subjectAntioxidants - Ús terapèutic
dc.subject.meshLiver Diseases
dc.subject.mesh/drug therapy
dc.subject.meshAntioxidants
dc.subject.mesh/therapeutic use
dc.titleCerium Oxide Nanoparticles: A New Therapeutic Tool in Liver Diseases
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/antiox10050660
dc.subject.decsenfermedades hepáticas
dc.subject.decs/farmacoterapia
dc.subject.decsantioxidantes
dc.subject.decs/uso terapéutico
dc.relation.publishversionhttps://doi.org/10.3390/antiox10050660
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Casals G] Service of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d’Investigacions, Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Comission for the Biochemical Assessment of Hepatic Disease-SEQCML, Barcelona, Spain. [Perramón M, Portolés I, Fernández-Varo G] Service of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d’Investigacions, Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. [Casals E] School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, China. [Morales-Ruiz M] Service of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d’Investigacions, Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Comission for the Biochemical Assessment of Hepatic Disease-SEQCML, Barcelona, Spain. Departament of Biomedicine, University of Barcelona, arcelona, Spain. [Puntes V] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Institut Català de Nanociència i Nanotecnologia (ICN2), CSIC, The Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
dc.identifier.pmid33923136
dc.identifier.wos000653485100001
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/SAF15-64126-R
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/RTI2018-094734-B-C21
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PID2019-105502RB-I00
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F00774
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/PI15%2F00077
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record